Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis

Journal of Molecular Modeling

Volumn 20, Issue 1, 2014, Pages

  Al Sha'er, Mahmoud A ^a   Khanfar, Mohammad A ^b   Taha, Mutasem O ^b  

^a ZARQA UNIVERSITY   (Jordan)

^b UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Anti inflammatory; Anticancer; Ligand based analysis; Serine peptidase; Urokinase plasminogen activator

Indexed keywords

ANTINEOPLASTIC AGENT; LIGAND; SERINE PROTEINASE INHIBITOR; UROKINASE;

ALGORITHM; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; DRUG DEVELOPMENT; HUMAN; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC;

ALGORITHMS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; ROC CURVE; SERINE PROTEINASE INHIBITORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84892689293     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-014-2080-4     Document Type: Article

References (68)

1. Rosenberg S (1999) The urokinase-type plasminogen activator and its receptor in cancer. Annu Rep Med Chem 34:121-128
2. Fazioli F, Blasi F (1994) Urokinase-type plasminogen activator and its receptor: New targets for anti-metastatic therapy? Trends Pharmacol Sci 15:25-29
3. Evans DM, Sloan-Stakleff KD (1998) Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer. Invasion Metastasis 18:252-260
4. Stacey MC, Burnand KG, Mahmoud-Alexandroni M, Gaffney PJ, Bhogal BS (1993) Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers. Br J Surg 80:596-599
5. Palolahti M, Lauharanta J, Stephens RW, Kuusela P, Vaheri A (1993) Proteolytic activity in leg ulcer exudate. Exp Dermatol 2:29-37
6. Rogers AA, Burnett S, Moore JC, Shakespeare PG, John Chen WY (1995) Involvement of proteolytic enzymes - plasminogen activators and matrix metalloproteinases - in the pathophysiology of pressure ulcers. Wound Repair Regen 3:273-283
7. Wysocki AB, Kusakabe AO, Chang S, Tuan T-L (1999) Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. Wound Repair Regen 7:154-165
8. Matthews H, Ranson M, Tyndall JDA, Kelso MJ (2011) Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA). Bioorg Med Chem Lett 21:6760-6766
9. West CW, Adler M, Arnaiz D, Chen D, Chu K, Gualtieri G, Ho E, Huwea C, Light D, Phillips G, Pulk R, Sukovich D, Whitlow M, Yuan S, Bryant J (2009) Identification of orally bioavailable, non-amidine inhibitors of urokinase plasminogen activator (uPA). Bioorg Med Chem Lett 19:5712-5715
10. Pandya V, Jain M, Chakrabarti G, Soni H, Parmar B, Chaugule B, Patel J, Joshi J, Joshi N, Rath A, Raviya M, Shaikh M, Sairam KVVM, Patel H, Patel P (2011) Discovery of inhibitors of plasminogen activator inhibitor-1: Structure-activity study of 5-nitro-2-phenoxybenzoic acid derivatives. Bioorg Med Chem Lett 21:5701-5706
11. Ye B, Bauer S, Buckman BO, Ghannam A, Griedel BD, Khim S-K, Lee W, Sacchi KL, Shaw KJ, Liang A, Wu Q, Zhao Z (2003) Synthesis and biological evaluation of menthol-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1). Bioorg Med Chem Lett 13:3361-3365
12. Gopalsamy A, Kincaid SL, Ellingboe JW, Groeling TM, Antrilli TM, Krishnamurthy G, Aulabaugh A, Friedrichsb GS, Crandall DL (2004) Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1. Bioorg Med Chem Lett 14:3477-3480
13. Beeley RA, Sage NC (2003) GPCRs: An update on structural approaches to drug discovery. Targets 2:19-25
14. Klebe G (2006) Virtual ligand screening: Strategies, perspectives and limitations. Drug Discov Today 11:580-594
15. Steuber H, Zentgraf M, Gerlach C, Sotriffer CA, Heine A, Klebe GJ (2006) Expect the unexpected or caveat for drug designers: Multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions. Mol Biol 363:174-187
16. Stubbs MT, Reyda S, Dullweber F, Moller M, Klebe G, Dorsch D, Mederski W, Wurziger H (2002) pH-dependent binding modes observed in trypsin crystals: Lessons for structure-based drug design. Chem Biol Chem 3:246-249
17. DePristo MA, de Bakker PIW, Blundell TL (2004) Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography. Structure 12:831-838
18. Mertens HD, Kjaergaard M, Mysling S, Gårdsvoll H, Jørgensen TJ, Svergun DI, Ploug M (2012) A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). J Biol Chem 287:34304-34315
19. Taha MO, Bustanji Y, Al-Ghussein MAS, Mohammad M, Zalloum H, Al-Masri IM, Atallah N (2008) Pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening reveal potent glycogen synthase kinase-3β inhibitory activities for cimetidine, hydroxychloroquine and gemifloxacin. J Med Chem 51:2062-2077
20. Taha MO, Atallah N, Al-Bakri AG, Paradis-Bleau C, Zalloum H, Younis K, Levesque RC (2008) Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening. Bioorg Med Chem 16:1218-1235
21. Taha MO, Bustanji Y, Al-Bakri AG, Yousef M, Zalloum WA, Al-Masri IM, Atallah N (2007) Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening. J Mol Graph Model 25:870-884
22. Al-masri IM, Mohammad MK, Taha MO (2008) Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening. Chem Med Chem 3:1763-1779
23. Taha MO, Dahabiyeh LA, Bustanji Y, Zalloum H, Saleh S (2008) Combining ligand-based pharmacophore modeling, QSAR analysis and in-silico screening for the discovery of new potent hormone sensitive lipase inhibitors. J Med Chem 51:6478-6494
24. Al-Nadaf A, Abu Sheikha G, Taha MO (2010) Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent β-secretase inhibitory leads. Bioorg Med Chem 18:3088-3115
25. Abu-Hammad AM, Taha MO (2009) Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors. J Chem Inf Model 49:978-996
26. Al-Sha'er MA, VanPatten S, Al-Abed Y, Taha MO (2013) Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors. J Mol Graph Model 42:104-114
27. Al-Sha'er MA, Taha MO (2010) Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem 45:4316-4330
28. Al-Sha'er MA, Taha MO (2010) Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors. J Chem Inf Model 50:1706-1723
29. Barber CG, Dickinson RP (2002) Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-substituted-5-halo-2-pyridinyl) guanidines. Bioorg Med Chem Lett 12:185-187
30. Subasinghe NL, Illig C, Hoffman J, Rudolph MJ, Wilson KJ, Soll R, Randle T, Green D, Lewandowski F, Zhang M, Bone R, Spurlino J, DesJarlais R, Deckman I, Molloy CJ, Manthey C, Zhou Z, Sharp C, Maguire D, Crysler C, Grasberger B (2001) Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors. Bioorg Med Chem Lett 11:1379-1382
31. Barber CG, Dickinson RP, Fish PV (2004) Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-Isoquinolinylguanidines. Bioorg Med Chem Lett 14:3227-3230
32. Barber CG, Dickinson RP, Horne VA (2002) Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-pyridinylguanidines. Bioorg Med Chem Lett 12:181-184
33. Spencer JR, McGee D, Allen D, Katz BA, Luong C, Sendzik M, Squires N, Mackman RL (2002) 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorg Med Chem Lett 12:2023-2026
34. Wendt MD, Geyer A, McClellan WJ, Rockway TW, Weitzberg M, Zhao X, Mantei R, Stewart K, Nienaber V, Klinghofera V, Giranda VL (2004) Interaction with the S1b-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors. Bioorg Med Chem Lett 14:3063-3068
35. Rudolph MJ, Illig CR, Subasinghe NL, Wilson KJ, Hoffman JB, Randle T, Green D, Molloy CJ, Soll RM, Lewandowski F, Zhang M, Bone R, Spurlino JC, Deckman IC, Manthey C, Sharp C, Maguire D, Grasberger BL, DesJarlais RL, Zhou Z (2002) Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors. Bioorg Med Chem Lett 12:491-495
36. StOrzebecher J, Vieweg H, Steinmetzer T, Schweinitz A, Stubbs MT, Renatus M, WikstrOm P (1999) 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 9:3147-3152
37. - (2005) CATALYST 4.11 users' manual. Accelrys Software, San Diego
38. Sheridan RP, Kearsley SK (2002) Why do we need so many chemical similarity search methods? Drug Discov Today 7:903-911
39. Sutter J, Güner O, Hoffmann R, Li H, Waldman M (2000) In: Güner OF (ed) Pharmacophore perception, development, and use in drug design. International University Line, La Jolla, pp 501-511
40. Kurogi Y, Güner OF (2001) Pharmacophore modeling and three dimensional database searching for drug design using catalyst. Curr Med Chem 8:1035-1055
41. Poptodorov K, Luu T, Langer T, Hoffmann R (2006) In: Hoffmann RD (ed) Methods and principles in medicinal chemistry. Pharmacophores and pharmacophores searches, vol 2. Wiley-VCH, Weinheim, pp 17-47
42. Li H, Sutter J, Hoffmann R (2000) In: Güner OF (ed) Pharmacophore perception, development, and use in drug design. International University Line, La Jolla, pp 173-189
43. Bersuker IB, Bahçeci S, Boggs JE (2000) In: Güner OF (ed) Pharmacophore perception, development, and use in drug design. International University Line, La Jolla, pp 457-473
44. - (2005) CERIUS2 LigandFit user manual (version 4.10). Accelrys, San Diego, pp 3-48
45. Fischer R (1966) The principle of experimentation illustrated by a psychophysical experiment. Hafner, New York, Chapter II
46. - (2005) CERIUS2, QSAR users' manual, version 4.10 Accelrys, San Diego, 43-88, 221-235, 237-250
47. Kirchmair J, Markt P, Distinto S, Wolber G, Langer T (2008) Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection - what can we learn from earlier mistakes? J Comput Aided Mol 22:213-228
48. Irwin JJ, Shoichet BK (2005) ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Comput Sci 45:177-182
49. Triballeau N, Acher F, Brabet I, Pin J-P, Bertrand H-O (2005) Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 48:2534-2547
50. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623
51. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 46:3-26
52. uPA Activity Assay kit Cat.No. ECM600. http://www.millipore.com/ catalogue/item/ecm600
53. Van Drie JH (2003) Pharmacophore discovery - lessons learned. Curr Pharm 9:1649-1664
54. Ramsey LF, Schafer WD (1997) The statistical sleuth, 1st edn. Wadsworth, Belmont
55. Verdonk ML, Marcel L, Berdini V, Hartshorn MJ, Mooij WTM, Murray CW, Taylor RD, Watson P (2004) Virtual screening using protein-ligand docking: Avoiding artificial enrichment. J Chem Inf Comput Sci 44:793-806
56. Clement OO, Mehl AT (2000) Pharmacophore perception, development, and use in drug design. In: Guner OF (ed) IUL biotechnology series. International University Line, La Jolla, pp 71-84
57. Wendt MD, Rockway TW, Geyer A, McClellan W, Weitzberg M, Zhao X, Mantei R, Nienaber VL, Stewart K, Klinghofer V, Giranda VL (2004) Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution. J Med Chem 47:303-324
58. Vassalli J-D, Belin D (1987) Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 214:187-191
59. Roy K, Chakraborty P, Mitra I, Ojha PK, Kar S, Narayan R (2013) Some case studies on application of "rm2" metrics for judging quality of QSAR predictions: emphasis on scaling of response data. J Comput Chem 34:1071-1082
60. Roy K, Mitra I (2011) On various metrics used for validation of predictive QSAR models with applications in virtual screening and focused library design. Comb Chem High Throughput Screen 14:450-474
61. Roy K, Mitra I, Kar S, Ojha PK, Das RN, Kabir H (2012) Comparative studies on some metrics for external validation of QSPR models. J Chem Inf Model 52:396-408
62. Ojha PK, Mitra I, Das RN, Roy K (2011) Further exploring rm2 metrics for validation of QSPR models dataset. Chemom Intell Lab Syst 107:194-205
63. Shi LM, Fang H, Tomg W, Wu J, Perkins R, Blair RM, Branham WS, Dial SL, Moland CL, Sheenan DM (2001) QSAR models using a large diverse set of estrogens. J Chem Inf Comput Sci 41:186-195
64. Golbraikh A, Tropsha A (2002) Beware of q2. J Mol Graph Model 20(4):269-276
65. Tropsha A (2010) Best practices for QSAR model development, validation, and exploitation. Mol Inf 29:476-488
66. Mita I, Saha A, Roy K (2010) Exploring quantitative structure-activity relationship studies of antioxidant phenolic compounds obtained from traditional Chinese medicinal plants. Mol Simulat 36:1067-1079
67. http://aptsoftware.co.in/DTCMLRWeb
68. http://www.aptsoftware.co.in/rmsquare